Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetastarch vs Albumin in Off-Pump CABG
NCT00307138Phase 3Completed
- Sponsor
- Kaiser Permanente
- Start
- Sep 2004
- Modality
- Polymer-based Nanoparticles, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hextend in hypovolemia (2 arms), sponsored by Kaiser Permanente. Primary endpoints: Number of units of packed red blood cells transfused within the first 24 hours after surgery, Number of units of fresh-frozen plasma transfused within the first 24 hours after surgery and 1 more. Started Sep 2004; status: completed.
02
Drugs
hextend
03
Conditions
hypovolemia
Beyond the preview
Go deeper on NCT00307138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307138.